The HDAC1 Knockout A-549 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal cell population derived from A-549 human lung adenocarcinoma epithelial cells, engineered to disrupt the HDAC1 gene. This knockout model serves as a loss-of-function tool for investigating the roles of histone deacetylase 1 in chromatin remodeling, transcriptional regulation, and cancer cell biology.
A-549 cells are an adherent epithelial line established from a 58-year-old Caucasian male with lung adenocarcinoma. These cells exhibit characteristics of type II alveolar epithelium, including expression of surfactant proteins, and are widely employed as a model for non-small cell lung cancer (NSCLC), respiratory infection studies, and drug metabolism investigations. Their well-characterized genetic and phenotypic properties make them a robust platform for studying epigenetic modifiers in lung carcinogenesis.
HDAC1 functions as a catalytic subunit within multiprotein complexes such as Sin3A, NuRD (interacting with MTA1 and MBD3), and CoREST, where it removes acetyl groups from lysine residues on histones H3 and H4, leading to chromatin condensation and transcriptional silencing. It is regulated by upstream signals including Sp1, p53, NF-??B, and phosphorylation by kinases such as CK2 and Aurora A downstream of PI3K/AKT. HDAC1 deacetylates non-histone substrates including p53, E2F1, and Rb, thereby influencing cell cycle progression and apoptosis. Its activity represses key tumor suppressor genes like p21/WAF1 and BIM, while also modulating cyclin D1 and E-cadherin expression.
Disruption of HDAC1 in A-549 lung adenocarcinoma cells relieves transcriptional repression of tumor suppressors, resulting in increased histone acetylation at promoters of genes such as p21 and BIM, and concomitant growth inhibition and apoptosis. This polyclonal knockout population enables investigation of HDAC1??s contribution to the oncogenic phenotype of NSCLC, including its role in sustaining proliferation and evading cell death. The model is particularly relevant for exploring epigenetic mechanisms of tumorigenesis and for evaluating therapeutic strategies targeting HDAC complexes.
Researchers can employ this HDAC1 knockout cell population in a variety of assays, including western blotting to assess HDAC1 protein loss and global histone acetylation changes, chromatin immunoprecipitation (ChIP-qPCR) to map acetylation at specific gene promoters, and RT-qPCR to quantify de-repression of target genes such as p21 and BIM. Additional applications encompass cell proliferation assays (MTT, BrdU), apoptosis detection (Annexin V/PI staining), co-immunoprecipitation for identifying HDAC1 interaction partners, and HDAC enzymatic activity measurements. These cells also provide a controlled genetic background for testing HDAC inhibitor sensitivity and for elucidating HDAC1 client protein interactions in lung cancer. For further technical details or ordering information, please contact Ascent Research.
